Evidence map›Paper›PMID 35305664›Full record

ArticleCost effectiveness and resource allocation : C/E2022

Out-of-pocket payments for treatment of COVID-19 in Iran.

Ali Reza Yusefi, Gholamhossein Mehralian, Abdolvahed Khodamoradi, Roghaye Abbasi, Fatemeh Vatankhah, Fatemeh Heaidari, Peivand Bastani

Abstract read
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali Reza YusefiDepartment of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.
Gholamhossein MehralianSchool of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. gmehralian@gmail.com.ORCID http://orcid.org/0000-0002-3510-4614
Abdolvahed KhodamoradiDepartment of Health Policy and Economics, Social Security Research Institute, Tehran, Iran.
Roghaye AbbasiStudent Research Committee, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.
Fatemeh VatankhahStudent Research Committee, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.
Fatemeh HeaidariStudent Research Committee, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.
Peivand BastaniFaculty of Health and Behavioral Sciences, School of Dentistry, University of Queensland, Brisbane, QLD, 4072, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOut-of-pocket (OOP) is among the payment methods in Iran's health system. The present study aimed to examine the OOP treatment costs for patients with COVID-19 in Iran.

methodsA descriptive-analytical, cross-sectional study was conducted in 2021. In this study, the cost records of 550 patients with COVID-19 hospitalized in a referral center of COVID-19 were selected using the stratified random sampling method. The required data were collected using a researcher-made questionnaire. Data were analyzed by t-test, ANOVA, and Pearson's correlation coefficient in SPSS software version 23 at p = 0.05.

resultsThe total direct costs were 1,037,992.15 US $. Moreover, the shares of patients (OOP), basic insurance, government subsidy, supplementary insurance, discounts, and out-of-government subsidy in the total direct costs were US $ 92,231.21, 746,932.99 US $, 155,127.08 US $, 39,690.25 US $ and 4010.61 US $, respectively. In addition, the results confirmed that there was a positive and significant relationship between the patients' OOP payments and the length of stay. It also found that the patients' OOP payments are subject to the type of insurance program and discharge method.

conclusionAccording to the results, 8.89% of the total direct costs were directly paid out of the patients' pockets. The research findings confirm the urgent need to make decisions and implement effective interventions for COVID-19 disease by controlling risk factors and exploiting other countries' successful experiences and international organizations' recommendations to decrease the prevalence of the infected and consequently reduce the financial pressure of the disease on patients by approving the expansion of the insurance organizations' role.

Indexed as

CoronavirusCOVID-19HospitalOut-of-pocket payment

Identifiers

PMID35305664
PMCPMC8934129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.